Bob Valamehr, PhD, chief development officer at Fate Therapeutics, discusses the advantages of off-the-shelf CAR NK therapy in B-cell malignancies.
Bob Valamehr, PhD
Advertisement
Articles by Bob Valamehr, PhD
Advertisement
Latest Updated Articles
Advantages of Off-the-Shelf CAR NK Therapy in B-Cell MalignanciesPublished: May 1st 2020 | Updated:
Advertisement
Advertisement
Trending on CGTlive®
1
Naji Gehchan, MD, MBA, on Evaluating CAR-T KYV-101 for Generalized Myasthenia Gravis
2
Around the Helix: Cell and Gene Therapy Company Updates – October 29, 2025
3
Quarter Century Update: Thoughts on Reducing Costs of Goods
4
Quarter Century Update: Future Predictions for the Field
5
